Validation Data Gallery
Tested Applications
| Positive FC detected in | C57BL/6 mouse splenocytes |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
CL750-98168 targets CD45.2 in FC applications and shows reactivity with mouse samples.
| Tested Reactivity | mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | Peptide 相同性解析による交差性が予測される生物種 |
| Full Name | protein tyrosine phosphatase, receptor type, C |
| Gene Symbol | CD45 |
| Gene ID (NCBI) | 19264 |
| Conjugate | CoraLite® Plus 750 Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 755 nm / 780 nm |
| Form | Liquid |
| Purification Method | Protein A purification |
| Storage Buffer | PBS with 0.09% sodium azide , pH 7.3 |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
CD45, also known as protein tyrosine phosphatase, receptor type C, is a type I transmembrane protein expressed on the surface of all haematopoietic cells with the exception of erythrocytes and platelets (PMID: 3489673; 28615666). CD45 is a pan-haematopoietic cell marker and has been shown to be essential for T- and B-cell activation and signalling (PMID: 9429890; 16378097). Allelic variants of mouse CD45, CD45.1 (Ly5.1) and CD45.2 (Ly5.1), have been established as a marker system to track haematopoietic cells following congenic mouse bone marrow transplants (PMID: 28615666). CD45.2 is the common form and is expressed by most of the established strains, while CD45.1 is found in only a few like the SJL mouse strain (PMID: 3489673).
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for CL Plus 750 CD45.2 antibody CL750-98168 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |